Monthly research recap
Depression research: October 2026
What October 2026's 25 new studies found, synthesized from the papers below. All Depression research →
The synthesis
Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Depression, major depressive disorder, MDD, depressive disorder, treatment-resistant depression, then ranked by relevance.
Research indexed in October 2026 points in a broadly positive direction for rapid-acting treatments in treatment-resistant depression: a large phase 2b trial of intranasal mebufotenin and an interim esketamine-ECT trial in adolescents both reported symptom and suicidality benefits, and modeled and observational work favored ketamine/esketamine on cost and quality of life. Psilocybin findings were more equivocal, with a small pilot missing its primary anhedonia endpoint while secondary depression measures favored the 25 mg dose, and a review stressing uncertain durability. The main caveats are small samples in several studies, unblinded or modeled designs, short follow-up, and limited long-term safety data.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Effects of psilocybin with psychological support on anhedonia in treatment-resistant depression: A randomized controlled pilot trial. 2026 | RCT | 20 | Mixed | Psilocybin 25 mg missed the primary week-1 anhedonia endpoint, but secondary analyses showed greater anhedonia improvement at week 8 and greater MADRS improvement at weeks 1 and 8. |
| Psilocybin, cognitive stability and drinking reduction in co-occurring alcohol use disorder and depression: a pilot secondary analysis of a randomized, placebo-controlled trial 2026 | secondary analysis of RCT | 25 | Mixed | Psilocybin slowed cued task switching about a week after dosing and had inconsistent effects on feedback-driven flexibility, while depressive symptom improvement was not associated with cognitive change. |
| Autophagic Dysregulation in Depression 2026 | thesis (human and preclinical experiments) | Supports | Spermidine increased autophagy flux and reduced depressive symptom severity in humans, and psilocybin/psilocin enhanced autophagy flux in neuronal cells with modest astrocyte and reduced microglial effects. | |
| Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial. 2026 | phase 2b RCT | 193 | Supports | Single intranasal mebufotenin doses reduced MADRS scores more than a 0.3 mg comparator at day 29 (-11.1 and -12.5 vs -5.5 points), with higher response and remission rates and good tolerability. |
| Sex-related differences in outcomes following psilocybin or escitalopram: a Bayesian secondary analysis. 2026 | post hoc Bayesian reanalysis of RCT | 59 | Mixed | No outcome showed an overall sex difference across treatments; within psilocybin, females had lower post-treatment anxiety than males, but the sex-by-treatment interaction was inconclusive. |
| Evaluating whether a therapeutic dose of ketamine exposure during adolescence influences adult vulnerability in rats to commonly abused drugs. 2026 | controlled animal experiment | No effect | Adolescent ketamine exposure did not increase adult ethanol consumption or cocaine place preference in either sex. | |
| Low-dose ketamine modulates brain entropy in treatment-resistant depression: Results from two neuroimaging clinical trials. 2026 | secondary analysis of two RCTs | Supports | Low-dose ketamine increased brain entropy from baseline to day 3 in frontolimbic, cerebellar and neuromodulatory regions, which the authors suggest may relate to its antidepressant effects. | |
| Implicit Self-Death Associations and Symptoms of Depression and Anxiety: A Single-Case Experimental Design 2026 | single-case experimental design | 4 | Mixed | A brief mindfulness intervention significantly reduced anxiety but not depression, with no significant baseline-to-maintenance effects and no change in implicit self-death associations. |
| Esketamine-Associated Lower Urinary Tract Symptoms Suggestive of Bladder Overactivity in Treatment-Resistant Depression: A Case Report 2026 | case report | 1 | Opposes | The patient developed urinary urgency and pelvic discomfort after starting intranasal esketamine, improving with mirabegron and resolving after dosing was spaced out. |
| Adolescents and carers using mindfulness Therapy To END depression (ATTEND): study protocol for a parallel randomised controlled superiority trial of Mindfulness for Adolescents and Carers (MAC) for depression among young people aged 15 to 18 years old with an embedded economic evaluation 2026 | RCT protocol | 480 | Unclear | The protocol describes a trial of a mindfulness intervention plus treatment as usual versus treatment as usual alone, with no outcome results reported. |
| Ketamine Versus Electroconvulsive Therapy for Nonpsychotic Treatment-Resistant Depression: A Cost-Effectiveness Analysis 2026 | cost-effectiveness analysis | Supports | Modeled racemic ketamine yielded slightly more QALYs (0.024) than ECT at lower health care and societal costs over 29 weeks. | |
| What is the efficacy of low-dose ketamine for treating depression and other mental health conditions? 2026 | review | Supports | Reports moderate efficacy of ketamine as a rapid-acting treatment for treatment-resistant and bipolar depression, with limited long-term safety data requiring monitoring. | |
| Subanesthetic-dose esketamine-assisted electroconvulsive therapy for suicidal ideation in adolescents with major depressive disorder: Interim trial results 2026 | interim RCT report | 113 | Supports | Adjunctive esketamine during ECT produced faster reduction in suicidal ideation and higher response rates (76.8% vs 57.9%) than saline, with similar remission rates and no significant short-term cognitive decline. |
| Suicidality during intranasal (es)ketamine treatment: A retrospective cohort study. 2026 | retrospective cohort | 80 | Mixed | Mean suicidality decreased modestly during intranasal esketamine treatment, but transient or sustained increases occurred in a minority and higher baseline suicidality predicted later worsening. |
| Spatiotemporal remodeling in habenula marks the onset of depression-related phenotypes 2026 | animal study | Supports | Chronic stress produced temporally organized lateral habenula remodeling and depression-related phenotypes, and ketamine reversed the neuronal adaptations and exerted antidepressant effects when given at onset. | |
| Quality of Life in Patients with Treatment-Resistant Depression Treated with Intranasal Esketamine as Add-On Therapy to an SSRI—A Prospective, Comparative Study in Real-World Clinical Practice 2026 | prospective observational cohort | 60 | Supports | Both groups improved in quality of life and depressive severity, with larger absolute changes in the esketamine add-on group, though the authors caution against causal interpretation. |
| Psilocybin in Treatment-Resistant Depression: Weighing Rapid Antidepressant Effects Against Uncertain Durability 2026 | narrative review | Mixed | Concludes psilocybin with psychological support shows short-term antidepressant activity, with one phase 3 trial meeting its primary endpoint and another not confirming its response hypothesis, while specific drug effect and durability remain uncertain. | |
| Depression: Ketamine quiets an unruly habenula. 2026 | commentary | Supports | Describes evidence that the ~24-hour window of ketamine's antidepressant effects coincides with reduced habenula activation and aversive learning in healthy subjects. | |
| Esketamine alleviates the pain-depression dyad: insights from exploratory transcriptomic profiling and Wnt4-associated molecular alterations within the anterior cingulate cortex 2026 | animal experiment | Supports | A single esketamine dose alleviated pain hypersensitivity, behavioral despair and anhedonia, associated with Wnt4-related molecular changes in anterior cingulate cortex neurons. | |
| Real-world clinical outcomes under intravenous and subcutaneous esketamine protocols for treatment-resistant depression: a multicenter, retrospective study 2026 | retrospective chart review | 72 | Mixed | Response distribution favored IV over SC esketamine after six sessions but was not statistically significant, and categorical response did not differ at protocol endpoints; dissociation was more frequent with IV. |
| Effects of Mindfulness-Based Stress Reduction Combined With Perioperative Refined Nursing on Postoperative Sleep Disturbances, Anxiety, and Depression in Patients Undergoing Coronary Artery Bypass Grafting 2026 | retrospective cohort with propensity matching | 146 | Supports | Adding mindfulness-based stress reduction to perioperative nursing was associated with lower anxiety and depression scores, better sleep, and favorable cortisol, IL-6, TNF-alpha and orexin levels. |
| Longitudinal peripheral DNA methylation remodeling following ketamine-assisted psychotherapy in major depressive disorder 2026 | longitudinal observational | 10 | Supports | Depressive symptoms declined markedly after ketamine-assisted psychotherapy, alongside exploratory DNA methylation changes enriched for NOTCH1-related pathways. |
| Baseline Response Criterion and Changes in Emotional Bias as Markers of Esketamine Response in Treatment-Resistant Depression 2026 | observational cohort | 106 | Supports | Patients showed altered facial-emotion processing at baseline, and esketamine responders showed early increases in discrimination sensitivity and less negative categorization of neutral faces by week 4. |
| Intranasal Esketamine for Treatment-Resistant Depression: A Practical Clinical Guide to Patient Selection, Dosing, Combination Strategies and Adverse-Event Management 2026 | review | Mixed | Argues that esketamine approval trials excluded many real-world patients and leave prescribing questions unresolved, including whether 84 mg outperforms 56 mg and when response should be judged. | |
| The Hidden Therapeutic Bridge: Exploring Psilocybin’s Role in Depression, Inflammation, and Pain – A Narrative Review 2026 | narrative review | Supports | Argues that psilocybin and psilocin show therapeutic potential for depression, anxiety and pain, with mechanisms possibly involving inflammation, the default mode network and mystical experiences. |
Points of agreement
- Multiple rapid-acting agents (ketamine, esketamine, mebufotenin, psilocybin) show antidepressant signal in treatment-resistant depression.
- Esketamine add-on and adjunctive esketamine during ECT are associated with symptom and suicidality improvement in observational and interim trial data.
- Ketamine and esketamine appear to act on limbic and habenula circuitry and emotional processing.
- Reviews consistently flag limited long-term safety and durability data.
Conflicts
- Psilocybin results are inconsistent: one pilot missed its primary anhedonia endpoint while secondary depression measures favored the drug, and one phase 3 trial met its primary endpoint while another did not confirm its response hypothesis.
- Suicidality outcomes with esketamine are mixed, with modest mean improvement but transient or sustained worsening in a minority.
- IV versus SC esketamine response differences were not statistically significant despite directional favoring of IV.
Gaps
- Durability of antidepressant effects beyond weeks to a few months is largely unestablished.
- Several key studies are small pilots, single cases, or unblinded observational designs.
- Long-term safety data, including urinary and cognitive effects, are limited.
- Adolescent and real-world comorbid populations are underrepresented in trials.
- Optimal dosing (e.g., 56 vs 84 mg esketamine) and retreatment strategies remain unresolved.
- Blinding integrity and specific drug versus psychological support effects are uncertain.